Traxens Announces Partnership With COSCO
Traxens, a company that provides high-value data and services for the supply chain industry, announces today a major partnership with COSCO Shipping Logistics that aims to promote a full set of IoT data services based on Traxens cutting-edge smart container solutions. Both companies are carrying out a test program to provide IoT data services to COSCO Shipping Logistics’ large worldwide base of beneficial cargo owners (BCO) customers and aiming to join force in promoting supply chain digitalization. This follows the opening of Traxens’ China office – its first outside of France.
COSCO is a leading global shipping company and a container logistics operator in China. In partnering with COSCO, Traxens will be able to demonstrate its capacity in creating customer values through promoting its smart container solutions and digital services, and significantly contributing to the ongoing digitalization of the global container logistics industry. As the global supply chain becomes more and more competitive, improved tracking and smart data management is an increasingly important differentiation factor for all the major players in the shipping industry.
Through this partnership, COSCO will be able to offer premium data services to its large base of BCOs who are seeking door-to-door visibility and ever-increasing efficiency in their supply chains. This joint development in container supply chain digitalization marks a milestone in Traxens’ international expansion strategy and will help the company push forward with further business development in Asia.
“Our main focus as a business is to be able to create substantial customer value by delivering superior solution and services through technological innovation and global customer support capacity” said David Marchand, Traxens CEO. “Our partnership with COSCO will greatly benefit cargo owners and end-users and encourage further digitalization of the container logistics industry to the benefit of customers worldwide.”
“Traxens is delighted to be working with COSCO, providing its industry-proven smart container solutions to help streamline the company’s operations and enhance customers experience,” said Vincent Gu, managing director, Traxens Asia-Pacific. “Providing fleets with global visibility, exception management and business intelligence is what Traxens does best. By partnering up with global shipping companies such as COSCO we are able to demonstrate what our market-leading IoT solutions are capable of, giving client companies end-to-end shipment visibility and predictive insights that will benefit the end-users and the whole industry.”
“Through our partnership with Traxens, we aim to be at the forefront of digitalization and to maintain our leadership in the global container logistics industry ” said Sheng Liu, general manager of the container logistics division of COSCO SHIPPING Logistics. “As a leading global logistics company, we always pay close attention to the needs of our customers in their supply chain. We believe that the IoT services developed by Traxens are important to improve tracking and management of moving assets.”
About COSCO Shipping
COSCO SHIPPING Logistics Co., Ltd (COSCO SHIPPING Logistics), affiliated to CHINA COSCO SHIPPING CORPORATION LIMITED, is an international integrated logistics enterprise with shipping logistics as its core. It can provide modernized and professional whole-process logistics and supply chain solutions for customers at home and abroad. With a strong reputation and professional service capabilities, it is an important partner for governments, ports, railways, airports and large multinational companies.
The company, with headquarters in Beijing, is merged with CHINA COSCO Logistics Co., Ltd.(a part of COSCO Group), China Shipping Logistics Co., Ltd. (China Shipping Group) and China Shipping Agency Co., Ltd. (China Shipping Group). It was launched on December 21, 2016. China Ocean Shipping Tally Company was incorporated into COSCO SHIPPING Logistics after integration on September 18, 2017.
The company’s service network covers 30 provinces in China and many other countries and regions in Europe, America, Asia and Africa. There are over 600 sales and service points throughout the world; such broad sales and service networks provide customers with a full range of logistics solutions. Since its establishment, COSCO Shipping Logistics has won the Golden Pegasus Prize and has for many years been recognised as one of the National Advanced Logistics Enterprises.
http://www.cosco-logistics.com.cn/
About Traxens
Traxens drives digital transformation in the global supply chain. The company’s breakthrough IoT technology, data science expertise, global logistics experience and standards leadership unlock the value of real-time data generated from cargo assets shipped by sea, rail and road. Traxens is trusted by hundreds of global cargo owners, enabling them to reduce door-to-door transport costs, optimize their investments and minimize risk. By partnering with the world’s leading shipping lines, rail carriers and smart ports, Traxens helps all members of the global supply chain ecosystem improve decision making, operations and customer service. Traxens is privately held and headquartered in Marseille, France.
www.traxens.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005361/en/
Contact information
Géraldine Saunière
Director of Communications
Mail: g.sauniere@traxens.com
Tel: +33-695-915-899
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom